• Explore /
  • Poster
  • / Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

Abstract Poster

Authors

null

YunJung Kim

Clinical Trial Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

YunJung Kim , Boram Ok , Inkeun Park , Baek-Yeol Ryoo , Kyu-Pyo Kim , Changhoon Yoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05222971

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4180)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4180

Abstract #

TPS4180

Poster Bd #

496b

Abstract Disclosures

Similar Posters

First Author: Severine Guiu Lahaye

First Author: Yasser Ged

First Author: Sofia Palacio

First Author: Vaibhav Sahai